Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 9, Number 9—September 2003
Dispatch

Fluoroquinolone and Macrolide Treatment Failure in Pneumococcal Pneumonia and Selection of Multidrug-Resistant Isolates

Emilio Pérez-Trallero*†Comments to Author , José M. Marimon*, Luis Iglesias*, and Julián Larruskain*
Author affiliations: *Hospital Donostia, San Sebastián, Spain; †Universidad del País Vasco, San Sebastián, Spain

Main Article

Table 1

In vitro antibiotic susceptibilities determined by agar dilution in Streptococcus pneumoniae isolates

Drug MIC (μg/mL) for each isolate/specimen collected, by date
1st isolate/sputum, 1-26-2002 2nd isolate/sputum, 2-8-2002 3rd isolate/sputum, 2-20-2002 4th isolate/sputum, 2-20-2002 5th isolate/pleural fluid, 02-26-2002
Ciprofloxacin
2
32
16
16
16
Levofloxacin
2
16
16
16
16
Moxifloxacin
1
4
4
4
4
Gemifloxacin
0.06
0.5
0.5
0.5
0.5
Erythromycin (14-m macrolide)
0.25
2
>128
>128
>128
Clarithromycin (14-m macrolide)
0.25
2
>128
>128
>128
Azithromycin (15-m macrolide)
0.5
4
>128
>128
>128
Midekamycin (16-m macrolide)
0.5
4
128
64
16
Clindamycin
0.25
≤0.25
16
16
16
Quinupristin-dalfopristin a
1
32
>32
>32
2
Telithromycin ≤0.12 2 8 16 0.5

a Determined by E-test; m, membered.

Main Article

Page created: January 03, 2011
Page updated: January 03, 2011
Page reviewed: January 03, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external